Multigene Testing for Hereditary Cancer: When, Why, and How
- PMID: 28515260
- DOI: 10.6004/jnccn.2017.0089
Multigene Testing for Hereditary Cancer: When, Why, and How
Abstract
Multigene testing is a complicated area, with advantages and disadvantages of testing for hereditary cancer syndromes. Currently, NCCN does not endorse routing multiplex testing outside of a research setting, and/or intensive genetic counseling regarding risks and benefits. The 2017 NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian and Colorectal provide suggestions for mutation carriers identified by panel tests.
Copyright © 2017 by the National Comprehensive Cancer Network.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
